180 related articles for article (PubMed ID: 35984649)
1. Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic Leukemia.
Reglero C; Dieck CL; Zask A; Forouhar F; Laurent AP; Lin WW; Albero R; Miller HI; Ma C; Gastier-Foster JM; Loh ML; Tong L; Stockwell BR; Palomero T; Ferrando AA
Cancer Discov; 2022 Nov; 12(11):2646-2665. PubMed ID: 35984649
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-Mediated Induction of Relapse-Specific
Nguyen TTT; Tanaka Y; Sanada M; Hosaka M; Tamai M; Kagami K; Komatsu C; Somazu S; Harama D; Kasai S; Watanabe A; Akahane K; Goi K; Inukai T
Mol Pharmacol; 2023 Apr; 103(4):199-210. PubMed ID: 36669880
[TBL] [Abstract][Full Text] [Related]
3. Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.
Dieck CL; Tzoneva G; Forouhar F; Carpenter Z; Ambesi-Impiombato A; Sánchez-Martín M; Kirschner-Schwabe R; Lew S; Seetharaman J; Tong L; Ferrando AA
Cancer Cell; 2018 Jul; 34(1):136-147.e6. PubMed ID: 29990496
[TBL] [Abstract][Full Text] [Related]
4. Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.
Dieck CL; Ferrando A
Blood; 2019 May; 133(21):2263-2268. PubMed ID: 30910786
[TBL] [Abstract][Full Text] [Related]
5. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
Tzoneva G; Perez-Garcia A; Carpenter Z; Khiabanian H; Tosello V; Allegretta M; Paietta E; Racevskis J; Rowe JM; Tallman MS; Paganin M; Basso G; Hof J; Kirschner-Schwabe R; Palomero T; Rabadan R; Ferrando A
Nat Med; 2013 Mar; 19(3):368-71. PubMed ID: 23377281
[TBL] [Abstract][Full Text] [Related]
6. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
Tzoneva G; Dieck CL; Oshima K; Ambesi-Impiombato A; Sánchez-Martín M; Madubata CJ; Khiabanian H; Yu J; Waanders E; Iacobucci I; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Gastier-Foster JM; Loh ML; Kirschner-Schwabe R; Mullighan CG; Rabadan R; Ferrando AA
Nature; 2018 Jan; 553(7689):511-514. PubMed ID: 29342136
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of
Moriyama T; Liu S; Li J; Meyer J; Zhao X; Yang W; Shao Y; Heath R; Hnízda A; Carroll WL; Yang JJ
Mol Cancer Ther; 2019 Oct; 18(10):1887-1895. PubMed ID: 31358663
[TBL] [Abstract][Full Text] [Related]
8. NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells.
Somazu S; Tanaka Y; Tamai M; Watanabe A; Kagami K; Abe M; Harama D; Shinohara T; Akahane K; Goi K; Sugita K; Moriyama T; Yang J; Goto H; Minegishi M; Iwamoto S; Takita J; Inukai T
J Cell Mol Med; 2021 Nov; 25(22):10521-10533. PubMed ID: 34636169
[TBL] [Abstract][Full Text] [Related]
9. Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia.
Barz MJ; Hof J; Groeneveld-Krentz S; Loh JW; Szymansky A; Astrahantseff K; von Stackelberg A; Khiabanian H; Ferrando AA; Eckert C; Kirschner-Schwabe R
Blood; 2020 Mar; 135(12):921-933. PubMed ID: 31971569
[TBL] [Abstract][Full Text] [Related]
10. NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia.
Tulstrup M; Grosjean M; Nielsen SN; Grell K; Wolthers BO; Wegener PS; Jonsson OG; Lund B; Harila-Saari A; Abrahamsson J; Vaitkeviciene G; Pruunsild K; Toft N; Holm M; Hulegårdh E; Liestøl S; Griskevicius L; Punab M; Wang J; Carroll WL; Zhang Z; Dalgaard MD; Gupta R; Nersting J; Schmiegelow K
Leukemia; 2018 Dec; 32(12):2527-2535. PubMed ID: 30201983
[TBL] [Abstract][Full Text] [Related]
11. Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation.
Hnízda A; Fábry M; Moriyama T; Pachl P; Kugler M; Brinsa V; Ascher DB; Carroll WL; Novák P; Žaliová M; Trka J; Řezáčová P; Yang JJ; Veverka V
Leukemia; 2018 Jun; 32(6):1393-1403. PubMed ID: 29535428
[TBL] [Abstract][Full Text] [Related]
12. Effects of NT5C2 Germline Variants on 6-Mecaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia.
Jiang C; Yang W; Moriyama T; Liu C; Smith C; Yang W; Qian M; Li Z; Tulstrup M; Schmiegelow K; Crews KR; Zhang H; Pui CH; Evans W; Relling M; Bhatia S; Yang JJ
Clin Pharmacol Ther; 2021 Jun; 109(6):1538-1545. PubMed ID: 33124053
[TBL] [Abstract][Full Text] [Related]
13. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.
Meyer JA; Wang J; Hogan LE; Yang JJ; Dandekar S; Patel JP; Tang Z; Zumbo P; Li S; Zavadil J; Levine RL; Cardozo T; Hunger SP; Raetz EA; Evans WE; Morrison DJ; Mason CE; Carroll WL
Nat Genet; 2013 Mar; 45(3):290-4. PubMed ID: 23377183
[TBL] [Abstract][Full Text] [Related]
14. Resistance revealed in acute lymphoblastic leukemia.
Aster JC; DeAngelo DJ
Nat Med; 2013 Mar; 19(3):264-5. PubMed ID: 23467232
[No Abstract] [Full Text] [Related]
15. Screening for gene mutations: will identification of NT5C2 mutations help predict the chance of relapse in acute lymphoblastic leukemia?
Meyer JA; Carroll WL; Bhatla T
Expert Rev Hematol; 2013 Jun; 6(3):223-4. PubMed ID: 23782074
[No Abstract] [Full Text] [Related]
16. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
Li B; Brady SW; Ma X; Shen S; Zhang Y; Li Y; Szlachta K; Dong L; Liu Y; Yang F; Wang N; Flasch DA; Myers MA; Mulder HL; Ding L; Liu Y; Tian L; Hagiwara K; Xu K; Zhou X; Sioson E; Wang T; Yang L; Zhao J; Zhang H; Shao Y; Sun H; Sun L; Cai J; Sun HY; Lin TN; Du L; Li H; Rusch M; Edmonson MN; Easton J; Zhu X; Zhang J; Cheng C; Raphael BJ; Tang J; Downing JR; Alexandrov LB; Zhou BS; Pui CH; Yang JJ; Zhang J
Blood; 2020 Jan; 135(1):41-55. PubMed ID: 31697823
[TBL] [Abstract][Full Text] [Related]
17. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
Mitra AK; Crews KR; Pounds S; Cao X; Feldberg T; Ghodke Y; Gandhi V; Plunkett W; Dolan ME; Hartford C; Raimondi S; Campana D; Downing J; Rubnitz JE; Ribeiro RC; Lamba JK
J Pharmacol Exp Ther; 2011 Oct; 339(1):9-23. PubMed ID: 21712425
[TBL] [Abstract][Full Text] [Related]
18. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.
Zgheib NK; Akika R; Mahfouz R; Aridi CA; Ghanem KM; Saab R; Abboud MR; Tarek N; El Solh H; Muwakkit SA
Pediatr Blood Cancer; 2017 Jan; 64(1):146-150. PubMed ID: 27577869
[TBL] [Abstract][Full Text] [Related]
19. [NT5C2 expression in children with acute leukemia and its clinical significance].
Wang Y; An X; Liu J; Zhang N; Liu Z; Liang S; Yu J
Zhonghua Xue Ye Xue Za Zhi; 2015 Sep; 36(9):748-53. PubMed ID: 26462774
[TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations.
Toksvang LN; Lee SHR; Yang JJ; Schmiegelow K
Leukemia; 2022 Jul; 36(7):1749-1758. PubMed ID: 35654820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]